Oxford Ledge
Search
Market prices for ZTS are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Zoetis Inc. (NYSE: ZTS) is a drug manufacturer. Figures from SEC EDGAR; updated 2026-10-19 19:07 UTC.
The company manufactures and distributes animal health products sold in more than 100 countries, with some products produced at sole-source manufacturing sites where minor deviations can cause delays or recalls. The company's success depends on maintaining customer perceptions of product quality and safety, which contribute to brand loyalty even after patent protection expires. Revenue is significantly exposed to foreign currency fluctuations, with a substantial portion earned outside the U.S. dollar.
Summarized from Zoetis Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| EPS (TTM) | $6.12 |
| Return on equity | 80.25% |
| Debt/equity | 2.87 |
The company manufactures and distributes animal health products sold in more than 100 countries, with some products produced at sole-source manufacturing sites where minor deviations can cause delays or recalls.
Zoetis Inc.'s most recent SEC filing on record is a 8-K filed 2026-08-06. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 19:07 UTC. This page is also available as JSON at /api/data?ticker=ZTS and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ZTS and 5,000+ tickers.
Create a free account — keep ZTSGET /api/data?ticker=ZTS
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt